Tivicay (dolutegravir sodium) NDC 60760-748

NDC codes

FDA NDC Directory

Product NDC (as listed)60760-748Labeler and product segments. Claims need a package NDC.

Product NDC at billing width60760-0748Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
60760-748-07	60760074807	7 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (60760-748-07)Marketed from Jan 16, 2026

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Tivicay
Generic name (nonproprietary): dolutegravir sodium
Active ingredients: Dolutegravir sodium — 50 mg/1
Dosage form: Tablet, Film coated
Route: Oral
Labeler: ST. MARY'S MEDICAL PARK PHARMACY
Product type: Prescription drug
Marketing category: NDA — New Drug ApplicationApplication NDA 204790
Marketing start: Aug 13, 2013
Listing expires: Dec 31, 2027
Other FDA classes: HIV Integrase Inhibitors (Mechanism)Multidrug and Toxin Extrusion Transporter 1 Inhibitors (Mechanism)Organic Cation Transporter 2 Inhibitors (Mechanism)
Identifiers: Product ID 60760-748_526982bc-f7b7-0c37-e063-6394a90a6d6fSPL ID 526982bc-f7b7-0c37-e063-6394a90a6d6fSPL set ID 485bc9db-8665-9f5a-e063-6394a90a7921RxCUI 1433873, 1433879UNII 1Q1V9V5WYQ
Pharmacologic class: Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N460760074807 followed by a unit qualifier and the quantity

Package 60760-0748-07. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective May 22, 2026.

Indications (excerpt from the label)

TIVICAY and TIVICAY PD are indicated in combination with other antiretroviral agents for the treatment of HIV‑1 infection in adults (treatment-naïve or -experienced) and in pediatric patients (treatment-naïve or -experienced but integrase strand transfer inhibitor [INSTI]-naïve) aged at least 4 weeks and weighing at least 3 kg [see Microbiology ( 12.4 )]. TIVICAY is indicated in combination with rilpivirine as a complete regimen for the treatment of HIV-1 infection in adults to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies/ mL) on a stable antiretroviral regimen for at least 6 months with no history of treatment failure or…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under NDA 204790

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under NDA 204790
Product	Strength	Form · route	Labeler	Product NDC
Tivicaydolutegravir sodium	Dolutegravir sodium 10 mg/1	Tablet, Film coatedOral	ViiV Healthcare Company	49702-226
Tivicaydolutegravir sodium	Dolutegravir sodium 25 mg/1	Tablet, Film coatedOral	ViiV Healthcare Company	49702-227
Tivicaydolutegravir sodium	Dolutegravir sodium 50 mg/1	Tablet, Film coatedOral	ViiV Healthcare Company	49702-228